title: Cervical response to vaccination against HPV16 E7 in case of severe dysplasia.
abstract: OBJECTIVE
  To evaluate the tolerance to vaccination against human papillomavirus (HPV)16 E7 (in SB adjuvant ASO2B) and its histological and immunohistological effects on HPV16 associated high-grade cervical dysplasias associated with HPV16.
  
  
  METHODS
  Five patients with histologically demonstrated severe cervical dysplasia (CIN3) HPV16 positive were injected three times before conization was performed 2 months after the first injection. We studied cytological, histological, proliferative pattern and immune profile before and after vaccination. The slides were compared with those obtained from non-injected patients.
  
  
  RESULTS
  The injections were well tolerated and the specimens displayed a limited regression of the lesions. Nevertheless, massive CD4 and CD8 T cell lymphocytic infiltration was noticed after vaccination.
  
  
  CONCLUSIONS
  We conclude that the vaccination we used provides an obvious immune histological reaction in the HPV infected cervix and that the 2 months delay before the final step (conization) is done is probably too short.
authors.affiliation: Department of Obstetrics and Gynaecology, CUB Hopital Erasme, Route de Lennik 808, 1070 Brussels, Belgium. psimon@ulb.ac.be
authors.forename: Ph
authors.initials: P
authors.lastname: Simon
authors.forename: F
authors.initials: F
authors.lastname: Buxant
authors.forename: S
authors.initials: S
authors.lastname: Hallez
authors.forename: A
authors.initials: A
authors.lastname: Burny
authors.forename: I
authors.initials: I
authors.lastname: Fayt
authors.forename: V
authors.initials: V
authors.lastname: Anaf
authors.forename: J C
authors.initials: JC
authors.lastname: Noël
mesh_terms: D000293:Adolescent; D000328:Adult; D018949:Antigens, CD1 / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002584:Cervix Uteri / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009856:Oncogene Proteins, Viral / Q000276:immunology*; D027383:Papillomaviridae / Q000276:immunology*; D050725:Papillomavirus E7 Proteins; D030361:Papillomavirus Infections / Q000276:immunology / Q000628:therapy*; D012074:Remission Induction / Q000379:methods; D002578:Uterine Cervical Dysplasia / Q000276:immunology / Q000473:pathology / Q000601:surgery / Q000628:therapy* / Q000821:virology*; D014611:Vaccination / Q000379:methods
chemical_list: D018949:Antigens, CD1; C419393:CD1a antigen; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; C059731:oncogene protein E7, Human papillomavirus type 16